Trials / Completed
CompletedNCT04522310
ProAdrenomedullin Assessment of Multi-Organ Failure in COvid-19 Sepsis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 183 (actual)
- Sponsor
- Centre Hospitalier de Lens · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
COVID-19 is a worldwide pandemic. Around 5% of infected patients are admitted in ICU, mainly for respiratory failure. Outcome of these patients is linked to other organ failures. Optimal therapies are not defined so far. The sponsor want to assess the role of MR-ProADM as prognostic biomarker, and the impact of treatments (including supportive treatments) on MOF occurrence and outcome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | MR-Pro-ADM | Dosage of MR-pro-ADM |
Timeline
- Start date
- 2020-07-07
- Primary completion
- 2021-02-28
- Completion
- 2021-05-29
- First posted
- 2020-08-21
- Last updated
- 2021-08-05
Locations
8 sites across 1 country: France
Source: ClinicalTrials.gov record NCT04522310. Inclusion in this directory is not an endorsement.